Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 11/20 | 0.56 |
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910850 | 0.87 | CASP3 (0.58) | CASP3SENP8SENP7SENP6RAB9A | |
| SCHEMBL4923647 | 0.80 | RAB9A (0.64) | CASP3SENP8SENP7SENP6RAB9A | |
| SCHEMBL4914811 | 0.80 | SCD (0.66) | RAB9ANPC1PPARGNCOR2SMN1; SMN2 | |
| SCHEMBL4921043 | 0.80 | ALDH1A1 (0.55) | RAB9ANPC1PPARGNCOR2MAPT | |
| SCHEMBL4919063 | 0.79 | CASP3 (0.73) | CASP3SENP8SENP7SENP6RAB9A | |
| SCHEMBL4915134 | 0.78 | SCD (0.61) | RAB9ANPC1PPARGNCOR2MAPT | |
| SCHEMBL4918031 | 0.76 | NPC1 (0.63) | RAB9ANPC1POLBPPARGNCOR2 | |
| SCHEMBL4917530 | 0.76 | KMT2A (0.57) | RAB9ANPC1PPARGNCOR2MAPT | |
| SCHEMBL4917961 | 0.75 | ALDH1A1 (0.54) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL2655153 | 0.75 | RAB9A (0.56) | RAB9ANPC1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | claimed |
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | CASP3 2997/4885SENP8 492/4885SENP7 293/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | CASP3 3241/4885SENP8 961/4885SENP7 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.